168 related articles for article (PubMed ID: 9743699)
1. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Akakura K; Akimoto S; Furuya Y; Ito H
Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
Akakura K; Akimoto S; Ohki T; Shimazaki J
Urology; 1995 Apr; 45(4):700-4; discussion 704-5. PubMed ID: 7536369
[TBL] [Abstract][Full Text] [Related]
3. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
5. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Small EJ; Srinivas S
Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
[TBL] [Abstract][Full Text] [Related]
6. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Matsumoto K; Hagiwara M; Hayakawa N; Tanaka N; Ito Y; Maeda T; Ninomiya A; Nagata H; Nakamura S
Asian Pac J Cancer Prev; 2014; 15(8):3645-9. PubMed ID: 24870772
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
8. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Paul R; Breul J
Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
[TBL] [Abstract][Full Text] [Related]
10. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Okegawa T; Nutahara K; Higashihara E
Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
[TBL] [Abstract][Full Text] [Related]
11. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher HI; Kelly WK
J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
13. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
Sekido N; Kawai K; Akaza H; Koiso K
Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
[TBL] [Abstract][Full Text] [Related]
14. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Small EJ; Baron A; Bok R
Cancer; 1997 Nov; 80(9):1755-9. PubMed ID: 9351544
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogen withdrawal syndrome with cyproterone acetate.
Sella A; Flex D; Sulkes A; Baniel J
Urology; 1998 Dec; 52(6):1091-3. PubMed ID: 9836560
[TBL] [Abstract][Full Text] [Related]
18. Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.
Noguchi K; Teranishi J; Uemura H; Fujikawa N; Saito K; Murai T
Int J Urol; 2006 Sep; 13(9):1259-61. PubMed ID: 16984567
[TBL] [Abstract][Full Text] [Related]
19. [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens].
Hornák M; Bárdos A; Goncalves F
Rozhl Chir; 1997 Sep; 76(9):435-7. PubMed ID: 9471771
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Kelly WK; Scher HI
J Urol; 1993 Mar; 149(3):607-9. PubMed ID: 7679759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]